'Interesting Timing': Fauci Touts Monoclonal Antibody Treatments One Day After FDA Approves Pfizer Vax

Chris Menahan
Aug. 27, 2021

Pure coincidence, no doubt!

From NY Post:
COVID-19 sufferers can reduce their risk of hospitalization and death by up to 85 percent if they receive monoclonal antibody treatments in the early stages of their illness, Dr. Anthony Fauci said Tuesday.

The White House chief medical adviser said that using the lab-made antibodies to fight the virus before a patient is hospitalized can prevent the chances of severe illness by between 70 and 85 percent.

"It is important to emphasize that this must be done early in infection and not wait, of course, until a person is sick enough to be hospitalized," Fauci said at a COVID-19 press briefing.

Regeneron's treatment costs $1,250 a dose. The federal government is currently covering the costs.

Several antibody treatments were greenlit for use in limited cases by the FDA through emergency use authorizations in May 2021 and Nov 2020.

From the FDA in May:
The data supporting this EUA for [GlaxoSmithKline's antibody treatment] sotrovimab are based on an interim analysis from a phase 1/2/3 randomized, double-blind, placebo-controlled clinical trial in 583 non-hospitalized adults with mild-to-moderate COVID-19 symptoms and a positive SARS-CoV-2 test result. Of these patients, 291 received sotrovimab and 292 received a placebo within five days of onset of COVID-19 symptoms. The primary endpoint was progression of COVID-19 (defined as hospitalization for greater than 24 hours for acute management of any illness or death from any cause) through day 29. Hospitalization or death occurred in 21 (7%) patients who received placebo compared to 3 (1%) patients treated with sotrovimab, an 85% reduction.

The FDA is carefully monitoring circulating viral variants and their sensitivity to monoclonal antibodies authorized to treat COVID-19, including sotrovimab. Laboratory testing showed that sotrovimab retains activity against the current circulating variants first reported in the United Kingdom, South Africa, Brazil, California, New York and India.

The EUA allows for sotrovimab to be distributed and administered as a 500 milligram single dose intravenously by health care providers. The EUA requires that fact sheets that provide important information about using sotrovimab in treating COVID-19 be made available to health care providers and to patients, parents and caregivers, including dosing instructions, potential side effects and drug interactions. Potential side effects of sotrovimab include anaphylaxis and infusion-related reactions, rash and diarrhea.
The death rate in the placebo group of 7% strikes me as unusually high.

It's interesting the way Big Pharma's drugs always seem to get Fauci's backing while cheap drugs studies indicate may be quite effective are blown off or derided.

For example, Fauci touted the hell out of remdesivir which appears to have been a bust.

The monoclonal antibody treatment appears to be only available for people who HHS considers "high risk."

I can't help but wonder if the evidence piling up that vaccines appear to be failing is causing Fauci et al. to finally look to alternatives.

Follow InformationLiberation on Twitter, Facebook, Gab, Minds, Parler and Telegram.

All original InformationLiberation articles CC 4.0

About - Privacy Policy